Skip to main
VRNA
VRNA logo

Verona Pharma (VRNA) Stock Forecast & Price Target

Verona Pharma (VRNA) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 53%
Buy 33%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Verona Pharma PLC has demonstrated significant momentum, with Ohtuvayre prescriptions increasing by over 35% each month in the fourth quarter of 2024, contributing to a revised full-year 2025 revenue forecast of $265 million. The company's impressive sales ramp and a fourth-quarter revenue total of approximately $42 million, which exceeded earlier projections, suggest a strong potential for long-term growth in Ohtuvayre's market presence. Additionally, with sufficient cash resources projected to support operations towards sustainable profitability, Verona Pharma is well-positioned to capitalize on the anticipated growth of its product candidate, ensifentrine, particularly in revenue streams from new markets not yet included in current valuations.

Bears say

Verona Pharma PLC faces significant challenges that contribute to a negative outlook on its stock, primarily centered around the anticipated commercial uptake of its product candidate, Ensifentrine, which may be slower than projected in both the U.S. and European markets. Additional concerns include potential competitive pressures that could hinder the optimization of Ensifentrine's value outside the U.S., as well as risks associated with the execution of partnerships aimed at enhancing its global market presence. Furthermore, the company may face the possibility of negative trial results for Ensifentrine, alongside the risk of long-term dilution, adding to the uncertainty surrounding its financial stability.

Verona Pharma (VRNA) has been analyzed by 15 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 33% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verona Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verona Pharma (VRNA) Forecast

Analysts have given Verona Pharma (VRNA) a Buy based on their latest research and market trends.

According to 15 analysts, Verona Pharma (VRNA) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $84.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $84.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verona Pharma (VRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.